Pharma Insight Briefings

Area of presentation – Analytical and Lab Services - Centralising stability studies – Managing risks

Karan Bagaria - Speaker Job Title: Business Development Director

  1. What are the current global trends driving the pharmaceutical sector you are working in? How does your company respond to those trends?

Growth in emerging markets is a key trend that is shaping the pharmaceutical outsourcing sector. In fact, pharmaceutical demand in emerging markets is expected to grow between 8 and 9 per cent per annum until 2020. Recipharm recently acquired the pharma division of Kemwell’s Indian operation in order to expand its global reach, enter emerging markets, access a highly-skilled workforce and offer cost effective development and manufacturing services, without compromising quality. The overall outlook for the CDMO market in general remains very positive, with increasing demand for outsourcing driving growth in both mature and emerging markets around the world.

2. What topic are you presenting at the Pharma Insight Briefings and why is this subject so important to the market at this time?

I will be presenting on the topic of ‘centralising stability studies – managing risks.’ Stability studies is a vital part of the drug development process, requiring careful management to mitigate potential risks. As the outsourcing sector continues to grow, more companies are taking the decision to outsource their stability testing requirements to generate cost savings and other efficiencies. As such, it’s an important time to consider the benefits and potential challenges of outsourcing to a contract laboratory and the critical factors to reduce risk during stability testing.

4. What can attendees to your session expect to gain and which challenges does this content address? Why should they include your presentation in their agenda?

Attendees can expect to gain a deeper insight into the key challenges and considerations when outsourcing stability studies and practical advice to enable better collaboration with contract partners. I will also explain the concept of a centralised approach to stability testing and how this can help to mitigate risks and most importantly, ensure the fastest possible times to market for drug developers.

5. How do you see your sector of the market evolving in the next 5 years?

I expect to see a growing trend towards outsourcing, particularly in emerging markets. Budgets will likely continue to be reduced across the sector driving a need for more affordable outsourced solutions that are focused on reducing time to market.